Life Sciences

China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
April 9, 2019
America’s ability to compete globally in biomedical innovation is being threatened.
March 25, 2019
NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain regular, steady increases.
March 7, 2019
America’s ascendance as the world’s leader in life-sciences innovation has been the result of thoughtful, intentional public policies, including robust funding for the National Institutes of Health
March 4, 2019
Misusing the “march-in right” provision of the Bayh-Dole Act could negatively impact U.S. life-sciences innovation and result in fewer new drugs.
February 25, 2019
A new study has sought to quantify this impact, tracking the availability of drugs released after 1981 that are designed to treat 66 diseases across 27 countries.
December 31, 2018
Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.
December 20, 2018
While many medical interventions—from vaccines, anesthesia, antibiotics, and even eyeglasses—have initially seemed like playing god, interventions to manipulate directly the heritable genetic endowment fundamental not only to what makes us human, but to what makes each of us unique, had never been seen before.
November 15, 2018
Stephen Ezell gave the keynote presentation at the Life Sciences Tennessee Annual Conference on innovation economics and how smart public policies can stimulate Tennessee’s growing life-sciences innovation sector.
November 10, 2018
As Rob Atkinson writes for The Hill, price controls and other steps to reduce drug company revenues would stifle knowledge generation and sharing, leaving future generations less access to effective new drugs than would otherwise be the case.
November 5, 2018
A considerable share of biopharma research “spills over” and contributes to knowledge discovery and drug development overall, not just in individual firms’ labs.

Pages